Tumor abstracts

1000 abstracts

Abstract Tumor-specific circulating cell-free DNA (ctDNA) and its clinical value in predicting response to palliative systemic treatment or survival in patients with pancreatic cancer: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy Congress:ESMO 2024, Search all connections
Abstract Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial Congress:ESMO 2024, Search all connections
Abstract Tumoral and peripheral immunophenotype of patients with stage II/III melanoma undergoing adjuvant immunotherapy following tumor resection Congress:ESMO 2024, Search all connections
Abstract Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity Congress:ESMO 2024, Search all connections
Abstract Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN Congress:ESMO 2024, Search all connections
Abstract Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma Congress:ESMO 2024, Search all connections
Abstract Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials Congress:ESMO 2024, Search all connections
Abstract Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) Congress:ESMO 2024, Search all connections
Abstract Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST Congress:ESMO 2024, Search all connections
Abstract Tumor-immune spatial interactions on NSCLC H&E slide images predicts immunotherapy response: Preliminary external validation Congress:ESMO 2024, Search all connections
Abstract Tumorspheres cultured from circulating cancer stem cells overexpress the innate checkpoint CD47 in breast cancer patients Congress:ESMO 2024, Search all connections
Abstract Tumor mutation burden and depression in lung cancer: Association with inflammation. Congress:ASCO 2019, Search all connections
Abstract Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment. Congress:ASCO 2019, Search all connections
Abstract Tumor molecular profiling in advanced pediatric brain tumors. Congress:ASCO 2019, Search all connections
Abstract Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma. Congress:ASCO 2019, Search all connections
Abstract Tumor-collagen digital proximity signature to indicate prognosis in diffuse large B-cell lymphoma. Congress:ASCO 2019, Search all connections
Abstract Tumor-associated myeloid derived suppressor cells of granulocytic nature as a potential biomarker for prognostication of response in treatment of diffuse large cell lymphoma. Congress:ASCO 2019, Search all connections
Abstract Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence. Congress:ASCO 2019, Search all connections
Abstract Tumor growth rate in metastatic adrenocortical carcinoma using two-dimensional computer tomography scan. Congress:ASCO 2019, Search all connections
Abstract Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (≤3.0 cm) after initial hepatectomy. Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden in biliary tract cancers with ERBB family or DNA damage repair gene mutations. Congress:ASCO 2019, Search all connections
Abstract Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers. Congress:ASCO 2019, Search all connections
Abstract Tumor stroma percentage (TSP) and intrinsic subtypes in stage II/III colon cancer: NRG Oncology/NSABP C-07 trial. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden reference materials for assay standardization. Congress:ASCO 2019, Search all connections
Abstract Tumor volumetric correlation with plasma cell free DNA (cfDNA) mutation detection in metastatic lung cancers. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden and spectrum in hormone receptor-positive breast cancer patients from India. Congress:ASCO 2019, Search all connections
Abstract Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. Congress:ASCO 2019, Search all connections
Abstract Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility. Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors. Congress:ASCO 2019, Search all connections
Abstract Tumor volume, circulating tumor cells, and cfDNA changes during radiotherapy in patients with head and neck cancer. Congress:ASCO 2019, Search all connections
Abstract Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study. Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody. Congress:ASCO 2019, Search all connections
Abstract Tumor and microenvironment evolution during chemotherapy combine with bevacizumab in colorectal cancer liver metastasis. Congress:ASCO 2019, Search all connections
Abstract Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109). Congress:ASCO 2019, Search all connections
Abstract Tumor specific DNA in bronchial lavage as a new diagnostic tool in lung cancer. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC). Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination. Congress:ASCO 2019, Search all connections
Abstract Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer. Congress:ASCO 2019, Search all connections
Abstract Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Congress:ASCO 2019, Search all connections
Abstract Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA). Congress:ASCO 2019, Search all connections
Abstract Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). Congress:ASCO 2019, Search all connections
Abstract Tumor expression of cGAS, not STING, negatively impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS ≥50. Congress:ASCO 2021, Search all connections
Abstract Tumor infiltrating lymphocytes (TILs) in endometrioid and clear cell ovarian carcinoma: Characterization, association with mismatch repair system deficiency and endometriosis, and prognostic implications. Congress:ASCO 2021, Search all connections
Abstract Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment. Congress:ASCO 2021, Search all connections
Abstract Tumor infiltrating lymphocytes and programmed death ligand-1 can identify different prognostic profiles in breast cancer. Congress:ASCO 2021, Search all connections
Abstract Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment. Congress:ASCO 2021, Search all connections
Abstract Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study. Congress:ASCO 2021, Search all connections
Abstract Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601). Congress:ASCO 2021, Search all connections
Abstract Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers. Congress:ASCO 2021, Search all connections
Abstract Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial. Congress:ASCO 2021, Search all connections
Abstract Tumor-educated platelets for breast cancer detection: Biological and technical insights. Congress:ASCO 2021, Search all connections
Abstract Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates. Congress:ASCO 2021, Search all connections
Abstract Tumor thrombosis in extremity soft tissue sarcomas. Congress:ASCO 2022, Search all connections
Abstract Tumor response heterogeneity, a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma. Congress:ASCO 2022, Search all connections
Abstract Tumor neutrophil extracellular traps and pretreatment neutrophils in association with progression-free survival in patients with metastatic non-small cell lung cancer receiving pembrolizumab alone or with chemotherapy. Congress:ASCO 2022, Search all connections
Abstract Tumor necrosis or cavity on baseline CT scan as a negative predictive biomarker for immune checkpoint inhibitors in advanced lung squamous cell carcinoma. Congress:ASCO 2022, Search all connections
Abstract Tumor mutation burden (TMB) and Notch1 gene alteration are associated with short disease-free survival in early laryngocarcinoma. Congress:ASCO 2022, Search all connections
Abstract Tumor-stroma interaction in cervical cancer: The prognostic importance of desmoplasia. Congress:ASCO 2022, Search all connections
Abstract Tumor microenvironment (TME) dynamics following capecitabine/oxaliplatin (CapeOx) plus pembrolizumab in patients with advanced gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Tumor marker testing among Medicare beneficiaries with cancer. Congress:ASCO 2022, Search all connections
Abstract Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis. Congress:ASCO 2022, Search all connections
Abstract Tumor copy number alterations were associated with primary endocrine resistance in ER+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy. Congress:ASCO 2022, Search all connections
Abstract Tumor cell budding as a prognostic and potentially therapeutically targetable biomarker in head and neck cancer. Congress:ASCO 2022, Search all connections
Abstract Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001). Congress:ASCO 2022, Search all connections
Abstract Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non–small cell lung cancer. Congress:ASCO 2022, Search all connections
Abstract Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. Congress:ASCO 2022, Search all connections
Abstract Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma. Organization:Department of Medica...,Drug:BRAF V600E,Melphalan,BRAF,Product:TMZ, Search all connections
Abstract Tumor immune microenvironment of different lesions in patients with multiple primary lung cancer. Organization:Jiangsu Simcere Diag...,Nanjing Simcere Medi...,The State Key Lab of...,Drug:immunotherapy,Target:tumor immune microen...,lung adenocarcinoma,driver genes,Congress:ASCO 2023, Search all connections
Abstract Tumor immune infiltrates and overall survival in non-small cell lung cancer are associated with an unsupervised radiomic signature. Organization:Memorial Sloan Kette...,Stony Brook Universi...,Congress:ASCO 2023, Search all connections
Abstract Tumor immune microenvironment (TIME) analysis of stage I lung adenocarcinoma with micropapillary pattern. Organization:Shengjing Hospital o...,The Medical Departme...,Jiangsu Simcere Diag...,Drug:CD69,IL6, Search all connections
Abstract Tumor immune environment in multiple primary malignancies involving colorectal cancers: Comparison with single primary colorectal cancers. Organization:Shanghai Fourth Peop...,Congress:ASCO 2023, Search all connections
Abstract Tumor immune environment in colitis-associated colorectal cancers: Comparison with sporadic colorectal cancers. Organization:Department of colore...,Department of Oncolo...,Congress:ASCO 2023, Search all connections
Abstract Tumor sensitization to PARP inhibitors by DNA damaging synthetically lethal acylfulvenes. Organization:Lantern Pharma,Drug:LP-100,LP-184,olaparib,Target:BRCA2,PTGR1, Search all connections
Abstract Tumor immunity portrait: An AI-driven molecular predictor combining tumor microenvironment and tumor mutational burden for immune checkpoint inhibitor response prediction. Organization:BostonGene Corporati...,Corp.,Drug:Immune checkpoint in...,Target:CTLA-4,PD-1,PD-L1,Congress:ASCO 2023, Search all connections
Abstract Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events. Organization:Banner MD Anderson C...,Geisinger Health Sys...,Brown University - L...,Drug:TTFields,Target:tumor progression,cellular processes,cancer cells,Congress:ASCO 2023, Search all connections
Abstract Tumor marker testing among Medicare beneficiaries with cancer after changes in insurance coverage for testing. Organization:Department of Popula...,Kaiser Permanente Co...,Geisinger Clinic, Da...,Drug:tumor marker,Target:tumor marker, Search all connections
Abstract Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). Organization:N.N. Petrov National...,N.N. Petrov National...,N.N. Petrov National...,Drug:carboplatin,anthracycline-taxane,NACT,Target:DNA, Search all connections
Abstract Tumor lysis syndrome in solid tumors: A retrospective cohort study of the National Inpatient Sample from 2016 to 2019. Organization:University of Califo...,Crozer-Chester Medic...,Hackensack Meridian ...,Congress:ASCO 2023,ASCO 2019, Search all connections
Abstract Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience. Organization:Virginia Commonwealt...,Virginia Commonwealt...,Drug:immunotherapy,Targeted Therapy,melanoma specific an...,Target:TI-ctDNA,Signatera™,Congress:ASCO 2023, Search all connections
Abstract Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer. Organization:National Cancer Cent...,Division of Genome B...,National Cancer Cent..., Search all connections
Abstract Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel). Clinical trial:BB2121-MM-001,Organization:Bristol Myers Squibb,Mount Sinai Medical ...,Dana-Farber Cancer I...,Drug:Ide-cel,Target:B-cell maturation an...,Congress:ASCO 2023, Search all connections
Abstract Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial. Organization:Fudan University Sha...,Department of Urolog...,Drug:abiraterone,Target:CYP17A1,Congress:ASCO 2023, Search all connections
Abstract Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study. Clinical trial:PSMA-617-01,Organization:BC Cancer-Vancouver ...,Vancouver Prostate C...,Tulane Cancer Center, Search all connections
Abstract Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness. Organization:Foundation Medicine,...,Mayo Clinic,Foundation Medicine ...,Drug:ICIs,Target:MSH2,BRAF,MSH6, Search all connections
Abstract Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions. Organization:Memorial Sloan Kette...,Sidney Kimmel Compre...,CHUM,Drug:MAPK-pathway directe...,EGFR targeted therap...,Target:EGFR-TKI sensitizing...,BRAF,MAPK, Search all connections
Abstract Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis. Clinical trial:CR108661,Organization:Janssen Research & D...,Janssen Research & D...,Janssen Research & D...,Drug:erdafitinib,Target:FGFR3,FGFR1,FGFR2, Search all connections
Abstract Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts. Organization:Charité – Universitä...,Corporate Member of ...,Humboldt-Universität..., Search all connections
Abstract Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. Clinical trial:NIR-DT-301,Organization:Medpace Inc,PharPoint Research,SpringWorks Therapeu...,Drug:Nirogacestat,Target:gamma secretase,Congress:ASCO 2023, Search all connections
Abstract Tumor Board Tuesday and awareness of novel therapies and toxicities in solid tumor oncology. Organization:University of Wiscon...,Tumor Board Tuesday,Sidney Kimmel Compre...,Drug:novel agent,novel agents,Congress:ASCO 2023, Search all connections
Abstract Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors. Clinical trial:2004-0069,Organization:The University of Te...,Cell Therapy Manufac...,Sarah Cannon Researc...,Drug:TILT-123,IL-2, Search all connections
Abstract Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC). Drug:PD-1/L1 checkpoint i...,Trastuzumab,Target:PD-1,PD-L1,Organization:Ren Ji Hospital,Renji Hospital Shang...,Clinical trial:NEO-IO,Congress:ASCO 2024, Search all connections
Abstract Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma. Organization:Taussig Cancer Cente...,Digestive Diseases a...,Congress:ASCO 2024, Search all connections
Abstract Tumor purity as confounder for the determination of tumor mutational burden (TMB). Organization:Heidelberg Universit...,Congress:ASCO 2024, Search all connections
Abstract Tumor-derived ILT3 inhibition to reshape the immunosuppressive microenvironment and potentiate the PD-L1 blockade immunotherapy in lung adenocarcinoma. Drug:ILT3,gp49B,PD-L1,Target:ApoE,ILT3 (gp49B),ILT3, Search all connections
Abstract Tumor origin identification through machine learning and gene expression profiling. Organization:HaploX Biotechnology...,Congress:ASCO 2024, Search all connections
Abstract Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer. Drug:ipilimumab,nivolumab,Target:CTLA-4,Programmed cell deat...,Organization:Frontier Science Fou...,Hospital Virgen De L...,Hôpital Arnaud de Vi..., Search all connections
Abstract Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer. Organization:Klinikum Starnberg,SAGA Diagnostics AB,Congress:ASCO 2024, Search all connections
Abstract Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC). Organization:Oschner Medical Cent...,Northwestern Univers...,Congress:ASCO 2024, Search all connections
Abstract Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer. Organization:Antwerpen,Congress:ASCO 2024, Search all connections
Abstract Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma. Organization:JHU,Johns Hopkins Brain ...,Sidney Kimmel Cancer...,Congress:ASCO 2024, Search all connections
Abstract Tumor microbiota, consensus molecular subtype and survival in colon adenocarcinoma. Organization:Molecular Oncology L...,INGEMM,Functional Genomics ...,Congress:ASCO 2024, Search all connections
Abstract Tumor treating fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study. Organization:General Hospital Asc...,University Hospital ...,University Hospital ..., Search all connections
Abstract Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma. Organization:H. Lee Moffitt Cance...,Department of Immuno...,Congress:ASCO 2024, Search all connections
Abstract Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. Organization:Miami Cancer Institu...,Poznan University of...,Collaborative Innova..., Search all connections
Abstract Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies. Organization:Early Phase Clinical...,Bergonie Institute, ...,Institut Bergonié, M..., Search all connections
Abstract Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. Organization:Flatiron Health, San...,Foundation Medicine,...,Foundation Medicine ...,Drug:pembrolizumab,anti-PD(L)1 therapy, Search all connections
Abstract Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation Congress:ESMO 2024, Search all connections
Abstract A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01 Congress:ESMO 2024, Search all connections
Abstract Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation Congress:ESMO 2024, Search all connections
Abstract Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade Congress:ESMO 2024, Search all connections
Abstract The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients Congress:ESMO 2024, Search all connections
Abstract Combining whole blood RNA-sequencing (WB-RNA) and circulating tumor DNA (ctDNA) for the early identification of patients (pts) without clinical benefit to immune checkpoint inhibitors (ICI) in metastatic urothelial cancer (mUC) Congress:ESMO 2024, Search all connections
Abstract Expression heterogeneity of ADC-related targets between primary tumors and metastatic lymph nodes in advanced urothelial cancers Congress:ESMO 2024, Search all connections
Abstract Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial Congress:ESMO 2024, Search all connections
Abstract Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort Congress:ESMO 2024, Search all connections
Abstract BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis Congress:ESMO 2024, Search all connections
Abstract Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma Congress:ESMO 2024, Search all connections
Abstract Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study Congress:ESMO 2024, Search all connections
Abstract Impact of proactive callback in patients with solid tumors receiving systemic therapy: A meta-analysis Congress:ESMO 2024, Search all connections
Abstract State of supportive care in oncology 2024: Tumor types, industry support, endpoints, and trial locations Congress:ESMO 2024, Search all connections
Abstract Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial Congress:ESMO 2024, Search all connections
Abstract Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study Congress:ESMO 2024, Search all connections
Abstract A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort Congress:ESMO 2024, Search all connections
Abstract Spatial analyses revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations Congress:ESMO 2024, Search all connections
Abstract Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC Congress:ESMO 2024, Search all connections
Abstract Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study Congress:ESMO 2024, Search all connections
Abstract Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas Congress:ESMO 2024, Search all connections
Abstract Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiâ€“colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiâ€“colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study Congress:ESMO 2024, Search all connections
Abstract Desmoid tumors: Experience of a Spanish reference center Congress:ESMO 2024, Search all connections
Abstract Pegylated liposomal doxorubicin in symptomatic desmoid tumor Congress:ESMO 2024, Search all connections
Abstract Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors Congress:ESMO 2024, Search all connections
Abstract Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study Congress:ESMO 2024, Search all connections
Abstract Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naÃ¯ve, advanced gastrointestinal stromal tumor (GIST) Congress:ESMO 2024, Search all connections
Abstract Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor Congress:ESMO 2024, Search all connections
Abstract The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens Congress:ESMO 2024, Search all connections
Abstract NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus Congress:ESMO 2024, Search all connections
Abstract Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy Congress:ESMO 2024, Search all connections
Abstract Inflammatory patterns of ascites in patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy Congress:ESMO 2024, Search all connections
Abstract Impact of subsequent anti-tumor therapies in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma receiving fruquintinib (F) plus paclitaxel (PTX) or placebo plus PTX in FRUTIGA study Congress:ESMO 2024, Search all connections
Abstract Association of tumor-draining lymph node metastatic patterns and neoadjuvant immunochemotherapy effectiveness in resectable non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA from the tumor-draining pulmonary vein as a biomarker in resected non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Cancer genome interpreter: A data-driven tool for tumor mutation interpretation Congress:ESMO 2024, Search all connections
Abstract Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform Congress:ESMO 2024, Search all connections
Abstract Universal circulating tumor DNA quantification using deep learning Congress:ESMO 2024, Search all connections
Abstract Convergent and divergent determinants of heterogeneity, biomarkers, and plasticity in thoracic and prostate neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract 21-day modified CAPTEM protocol is effective and safe for patients with advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT) Congress:ESMO 2024, Search all connections
Abstract A novel nomogram for predicting overall survival of small intestinal neuroendocrine tumors treated with PRRT Congress:ESMO 2024, Search all connections
Abstract Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry Congress:ESMO 2024, Search all connections
Abstract The efficacy of lower doses of everolimus in patients with advanced neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial Congress:ESMO 2024, Search all connections
Abstract Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206) Congress:ESMO 2024, Search all connections
Abstract Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry Congress:ESMO 2024, Search all connections
Abstract Intratumoral microbiota is associated with prognosis in Chinese patients with skin melanoma Congress:ESMO 2024, Search all connections
Abstract Multiomics clustering of patients with cutaneous melanoma to reveal survival trends based on tumor immune evasion features Congress:ESMO 2024, Search all connections
Abstract Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma Congress:ESMO 2024, Search all connections
Abstract High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma Congress:ESMO 2024, Search all connections
Abstract Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial Congress:ESMO 2024, Search all connections
Abstract A phase I trial of ATG-101, an investigational PD-L1Ã—4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAMÃ—4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7 Congress:ESMO 2024, Search all connections
Abstract Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort Congress:ESMO 2024, Search all connections
Abstract Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers Congress:ESMO 2024, Search all connections
Abstract CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment Congress:ESMO 2024, Search all connections
Abstract Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures Congress:ESMO 2024, Search all connections
Abstract ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1 Congress:ESMO 2024, Search all connections
Abstract Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study Congress:ESMO 2024, Search all connections
Abstract Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484 Congress:ESMO 2024, Search all connections
Abstract Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance Congress:ESMO 2024, Search all connections
Abstract Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients Congress:ESMO 2024, Search all connections
Abstract Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors Congress:ESMO 2024, Search all connections
Abstract A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms Congress:ESMO 2024, Search all connections
Abstract First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study Congress:ESMO 2024, Search all connections
Abstract Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC Congress:ESMO 2024, Search all connections
Abstract The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors Congress:ESMO 2024, Search all connections
Abstract Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFÎ²-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study Congress:ESMO 2024, Search all connections
Abstract Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I/II trial of ASP1570, a novel diacylglycerol kinase Î¶ inhibitor, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970) Congress:ESMO 2024, Search all connections
Abstract Lenvatinib plus drug-eluting bead transarterial chemoembolization with or without hepatic arterial infusion chemotherapy for hepatocellular carcinoma (> 7 cm) with portal vein tumor thrombosis: A retrospective multicenter cohort study Congress:ESMO 2024, Search all connections
Abstract HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trial Congress:ESMO 2024, Search all connections
Abstract Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening Congress:ESMO 2024, Search all connections
Abstract Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection Congress:ESMO 2024, Search all connections
Abstract Pyroptosis-related pattern depicts tumor microenvironment and predicts prognosis and efficacy in hepatocellular carcinoma patients receiving combined molecular targeted therapy and immune checkpoint inhibitors: A multi-omics study Congress:ESMO 2024, Search all connections
Abstract Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations Congress:ESMO 2024, Search all connections
Abstract Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer Congress:ESMO 2024, Search all connections
Abstract Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosis Congress:ESMO 2024, Search all connections
Abstract Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients Congress:ESMO 2024, Search all connections
Abstract Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling Congress:ESMO 2024, Search all connections
Abstract Genetic, epigenetic, and clinical significance of Wilmsâ€™ tumor 1 (WT1) gene in acute myeloid leukemia Congress:ESMO 2024, Search all connections
Abstract A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor Î± (FRÎ±)-expressing advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs) Congress:ESMO 2024, Search all connections
Abstract First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials Congress:ESMO 2024, Search all connections
Abstract Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study Congress:ESMO 2024, Search all connections
Abstract Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA Congress:ESMO 2024, Search all connections
Abstract Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study Congress:ESMO 2024, Search all connections
Abstract Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers Congress:ESMO 2024, Search all connections
Abstract Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER Congress:ESMO 2024, Search all connections
Abstract Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT) Congress:ESMO 2024, Search all connections
Abstract Detection of circulating tumor DNA and chromosome 3p25.3 gain in relapsed/refractory germ cell tumors and impact of salvage high-dose chemotherapy: Results from the Italian Germ Cell Cancer Group 04 study Congress:ESMO 2024, Search all connections
Abstract Outcomes of patients with testicular germ cell tumors in Latin-America Congress:ESMO 2024, Search all connections
Abstract Causes of death in patients with malignant adrenal tumors: A population-based analysis Congress:ESMO 2024, Search all connections
Abstract PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation Congress:ESMO 2024, Search all connections
Abstract HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I, multicenter trial (â€œKinLETâ€�) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age Congress:ESMO 2024, Search all connections
Abstract A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study Congress:ESMO 2024, Search all connections
Abstract A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies Congress:ESMO 2024, Search all connections
Abstract Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations Congress:ESMO 2024, Search all connections
Abstract MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors Congress:ESMO 2024, Search all connections
Abstract Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer) Congress:ESMO 2024, Search all connections
Abstract LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data Congress:ESMO 2024, Search all connections
Abstract CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease Congress:ESMO 2024, Search all connections
Abstract Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients Congress:ESMO 2024, Search all connections
Abstract Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor Congress:ESMO 2024, Search all connections
Abstract Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial Congress:ESMO 2024, Search all connections
Abstract First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)â€’SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results Congress:ESMO 2024, Search all connections
Abstract Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK Congress:ESMO 2024, Search all connections
Abstract Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study Congress:ESMO 2024, Search all connections
Abstract A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors Congress:ESMO 2024, Search all connections
Abstract Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors Congress:ESMO 2024, Search all connections
Abstract First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors Congress:ESMO 2024, Search all connections
Abstract Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D) Congress:ESMO 2024, Search all connections
Abstract Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD) Congress:ESMO 2024, Search all connections
Abstract Initial results from the phase I, first-in-human study of the covalent, PI3KÎ± inhibitor TOS-358 in patients with solid tumors, expressing PI3KÎ± mutations or amplifications Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901) Congress:ESMO 2024, Search all connections
Abstract Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort Congress:ESMO 2024, Search all connections
Abstract Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA mismatch repair deficient (dMMR) colorectal cancers Congress:ESMO 2024, Search all connections
Abstract Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study Congress:ESMO 2024, Search all connections
Abstract Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer (CRC) Congress:ESMO 2024, Search all connections
Abstract Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28 Congress:ESMO 2024, Search all connections
Abstract Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA guided therapeutic strategies for colorectal cancer patients with multiple small pulmonary-limited nodules: Updated results from the open-label, prospective, phase II cohort study Congress:ESMO 2024, Search all connections
Abstract Early changes in circulating tumor DNA (ctDNA) and outcome during systemic palliative treatment for metastatic colorectal cancer: A systematic review and meta-analysis â€” An initiative under the ctDNA RECIST program Congress:ESMO 2024, Search all connections
Abstract Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD Congress:ESMO 2024, Search all connections
Abstract Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping Congress:ESMO 2024, Search all connections
Abstract Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study Congress:ESMO 2024, Search all connections
Abstract Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients Congress:ESMO 2024, Search all connections
Abstract Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields Congress:ESMO 2024, Search all connections
Abstract Interfering with the tumor microenvironment of glioblastoma: An in vitro study Congress:ESMO 2024, Search all connections
Abstract A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment Congress:ESMO 2024, Search all connections
Abstract Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations Congress:ESMO 2024, Search all connections
Abstract Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial Congress:ESMO 2024, Search all connections
Abstract Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study Congress:ESMO 2024, Search all connections
Abstract Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US Congress:ESMO 2024, Search all connections
Abstract AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer Congress:ESMO 2024, Search all connections
Abstract EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project Congress:ESMO 2024, Search all connections
Abstract The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis Congress:ESMO 2024, Search all connections
Abstract Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2âˆ’ metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors Congress:ESMO 2024, Search all connections
Abstract Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02 Congress:ESMO 2024, Search all connections
Abstract Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up Congress:ESMO 2024, Search all connections
Abstract Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa Congress:ESMO 2024, Search all connections
Abstract First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients Congress:ESMO 2024, Search all connections
Abstract Optimizing breast cancer staging: Redefining tumor size classification using big data analytics Congress:ESMO 2024, Search all connections
Abstract Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC Congress:ESMO 2024, Search all connections
Abstract Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy Congress:ESMO 2024, Search all connections
Abstract Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy Congress:ESMO 2024, Search all connections
Abstract A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H) Congress:ESMO 2024, Search all connections
Abstract eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors Congress:ESMO 2024, Search all connections
Abstract Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2 Congress:ESMO 2024, Search all connections
Abstract Randomized phase II study of trabectedin/olaparib compared to physicianâ€™s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies Congress:ESMO 2024, Search all connections
Abstract Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301) Congress:ESMO 2024, Search all connections
Abstract Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors Congress:ESMO 2024, Search all connections
Abstract From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis Congress:ESMO 2024, Search all connections
Abstract HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms Congress:ESMO 2024, Search all connections
Abstract HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd) Congress:ESMO 2024, Search all connections
Abstract Analysis of tumor immune microenvironment with mIHC in Chinese non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients Congress:ESMO 2024, Search all connections
Abstract Exploiting gp100-specific antibodies isolated from immune checkpoint inhibitor-responsive melanoma patients to target tumor cells Congress:ESMO 2024, Search all connections
Abstract Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment Congress:ESMO 2024, Search all connections
Abstract Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy Congress:ESMO 2024, Search all connections
Abstract 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation Congress:ESMO 2024, Search all connections
Abstract Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype Congress:ESMO 2024, Search all connections
Abstract Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy Congress:ESMO 2024, Search all connections
Abstract Ipilimumab plus nivolumab (Ipi+Nivo) in patients with tumors harboring high tumor mutational burden or load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP) Congress:ESMO 2024, Search all connections
Abstract Integrating large data to unveil vulnerabilities for patients with hot tumors resistant to checkpoint inhibition Congress:ESMO 2024, Search all connections
Abstract Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Genomic landscape and prognostic impact of HER2 low-expressing tumors Congress:ESMO 2024, Search all connections
Abstract Comprehensive cancer genome profiling as supportive tool for treatment decision-making in patients with metastatic solid tumors: Real-world evidence-based meta-analysis and nationwide cancer registry data implementation Congress:ESMO 2024, Search all connections
Abstract A prospective comparative evaluation of automatic trial match tools in a molecular tumor board Congress:ESMO 2024, Search all connections
Abstract Comparative analysis of DNA and RNA-based NGS for detecting MET exon 14 skipping mutation in pan-solid tumor samples Congress:ESMO 2024, Search all connections
Abstract The association of changes in circulating tumor fraction and in actionable variant allele frequencies with clinical outcomes in real world diverse cohort of advanced patients treated with tyrosine kinase inhibitors Congress:ESMO 2024, Search all connections
Abstract Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies Congress:ESMO 2024, Search all connections
Abstract Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma Congress:ESMO 2024, Search all connections
Abstract Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC Congress:ESMO 2024, Search all connections
Abstract Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial Congress:ESMO 2024, Search all connections
Abstract Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial Congress:ESMO 2024, Search all connections
Abstract True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Congress:ESMO 2024, Search all connections
Abstract Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update Congress:ESMO 2024, Search all connections
Abstract Development of a next-generation sequencing diagnostics recommender tool in the framework of the molecular tumor board Freiburg Congress:ESMO 2024, Search all connections
Abstract Correlation of circulating tumor cells with cancer stage Congress:ESMO 2024, Search all connections
Abstract Feasibility of expanding tumor-infiltrating lymphocytes from cryopreserved tumor specimens after long-term storage Congress:ESMO 2024, Search all connections
Abstract The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates Congress:ESMO 2024, Search all connections
Abstract Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors Congress:ESMO 2024, Search all connections
Abstract Patient derived circulating tumor cell clusters for personalized chemotherapy Congress:ESMO 2024, Search all connections
Abstract Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into â€œhotâ€� tumors Congress:ESMO 2024, Search all connections
Abstract Small-extracellular vesicles derived from NSCLC cells dampen the CD8+ T cell response against tumor Congress:ESMO 2024, Search all connections
Abstract Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations Congress:ESMO 2024, Search all connections
Abstract Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract CT128 / 11 - A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC) Indication:Solid Tumors and Hem...,Product:targeted agents,IRX-2,Chemotherapy,Drug:Cisplatin,PD-1 antibody,targeted agents,Target:ALK, Search all connections
Abstract CT083 / 11 - Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study Indication:Small Intestine Aden...,Product:dabrafenib,Trametinib,Dabrafenib + Trameti...,Drug:dabrafenib plus tram...,dabrafenib,trametinib, Search all connections
Abstract CT107 / 4 - Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma Indication:Melanoma,Product:BO-112 + pembrolizum...,BO-112,Pembrolizumab,Drug:pembrolizumab,BO-112 plus pembroli...,Target:PD-1,CD8+CTL cells, Search all connections
Abstract BAFF LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND RESPONSE TO ANTI-TUMOR NECROSIS FACTOR TREATMENT Organization:University Hospital ...,Zurich University, Z...,Congress:EULAR 2012, Search all connections
Abstract B-CELL ACTIVATING FACTOR OF THE TUMOR NECROSIS FACTOR FAMILY (BAFF) IN POSTMENOPAUSAL RHEUMATOID ARTHRITIS PATIENTS WITH LOW BONE MASS: A POSSIBLE PROTECTIVE ROLE OF HYDROXYCHLOROQUINE Organization:Rheumatology and Cli...,Pharmacology and Tox...,Pharmacology departm...,Congress:EULAR 2014, Search all connections
Abstract AUTOSOMAL DOMINANT PERIODIC FEVER WITH AA AMYLOIDOSIS: TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME (TRAPS) IN A TURKISH FAMILY Organization:Rheumatology, Gulhan...,Congress:EULAR 2005, Search all connections
Abstract ASSOCIATIONS OF NON-SERIOUS INFECTIONS (NSIE) WITH TUMOR NECROSIS FACTOR ANTAGONISTS (TNFI): A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Organization:Rheumatology, Presby...,Statistics, Medical ...,Internal Medicine, P...,Congress:EULAR 2009, Search all connections
Abstract ASSOCIATION OF ATTITUDES TOWARD CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND TUMOR NECROSIS FACTOR INHIBITORS AND TREATMENT ADHERENCE IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, AND PSORIATIC ARTHRITIS: RESULTS FROM THE GLOBAL A Organization:GKM, Munich, Germany,AbbVie Inc., North C...,AbbVie Deutschland G...,Congress:EULAR 2015, Search all connections
Abstract ASSOCIATION BETWEEN TUMOR NECROSIS FACTOR RECEPTOR 1 (TNF R1) LEVELS AND CAROTID INTIMA MEDIA THICKNESS (IMT) IN MALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Organization:Institute of Rheumat...,Congress:EULAR 2006, Search all connections
Abstract ASSOCIATION BETWEEN TOBACCO SMOKING AND RESPONSE TO TUMOR NECROSIS FACTOR ALPHA INHIBITOR TREATMENT IN PSORIATIC ARTHRITIS: RESULTS FROM THE DANBIO REGISTRY Organization:Department of Rheuma...,Department of Rheuma...,The Danish Rheumatol...,Congress:EULAR 2014, Search all connections
Abstract ASSOCIATION BETWEEN TOBACCO SMOKING AND RESPONSE TO TUMOR NECROSIS FACTOR ALPHA INHIBITOR TREATMENT IN ANKYLOSING SPONDYLITIS: RESULTS FROM THE DANISH NATIONWIDE DANBIO REGISTRY Organization:Department of Rheuma...,The Danish Rheumatol...,Gentofte University ...,Congress:EULAR 2015, Search all connections
Abstract ASSOCIATION BETWEEN T-CELL PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA AND THE PRESENCE OF NODULAR DISEASE IN RHEUMATOID ARTHRITIS Organization:Department of Pathol...,Congress:EULAR 2003, Search all connections
Abstract ASSOCIATION BETWEEN SINGLE-NUCLEOTIDE POLYMORPHISMS IN TUMOR NECROSIS FACTOR-ALPHA GENE AND ANKYLOSING SPONDYLITIS IN CHINESE HAN POPULATION Organization:Rheumatology and Imm...,Changhai Hospital, N...,Medical Genetics Ins..., Search all connections
Abstract ASSOCIATION BETWEEN RHEUMATOID FACTOR STATUS AND DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS DUE TO INEFFECTIVENESS IN RHEUMATOID ARTHRITIS Organization:Nakatsugawa Municipa...,Nagoya University Gr...,Congress:EULAR 2019, Search all connections
Abstract ASSOCIATION BETWEEN INITIAL SERUM “TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS” (TWEAK) LEVEL AND TREATMENT RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) NEPHROPATHY Organization:Yangon Specialist Ho...,Yangon General Hospi...,Congress:EULAR 2020, Search all connections
Abstract ASSESSMENT OF SALARY GROWTH IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH AND WITHOUT ANTI-TUMOR NECROSIS FACTOR THERAPY Organization:Division of Arthriti...,AbbVie, Inc., North ...,Analysis Group, Inc....,Congress:EULAR 2015, Search all connections
Abstract ARGININE-RICH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (ANTI-VEGF) HEXAPEPTIDE INHIBITS COLLAGEN-INDUCED ARTHRITIS AND VEGF-STIMULATED PRODUCTIONS OF TUMOR NECROSIS FACTOR-ALPHA AND INTERLEUKIN-6 BY HUMAN MONOCYTES Organization:Department of Rheuma...,Congress:EULAR 2005, Search all connections
Abstract ARE THERE DIFFERENCES IN BASELINE CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS ACCORDING TO THE PRESENCE OF COMORBIDITIES? Organization:Arthritis Unit. Rheu...,Research Unit, Spani...,Group of Cellular Im..., Search all connections
Abstract ARE THERE DIFFERENCES IN BASAL COMORBIDITIES BETWEEN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT AND THOSE TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS? Organization:Arthritis Unit. Rheu...,Research Unit, Spani...,Rheumatology Dpt., H..., Search all connections
Abstract ARE ANY DIFFERENCES IN THE LOCATION OF BONE LESIONS BETWEEN BONE MALIGNANT TUMORS AND INFLAMMATORY OSTEOPATHIES? Organization:Saint-Petersburg cli...,Saint-Petersburg Sta...,Kirov’s regional chi...,Congress:EULAR 2019, Search all connections
Abstract ANTIPHOSPHOLIPID ANTIBODIES, INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-α IN ATHEROSCLEROTIC PROCESS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS Organization:Ultrasound Diagnosti...,Cardiology and Rheum...,Congress:EULAR 2017, Search all connections
Abstract ANTIBODIES TO TUMOR NECROSIS FACTOR-ALFA (ANTI-TNF) AND TO INTERFERON-GAMMA (ANTI-IFN-G) IN THE THERAPY OF RHEUMATOID ARTHRITIS (RA) Organization:Clinical Pharmacolog...,Institute of Rheumat...,Moscow City Oncology...,Congress:EULAR 2003, Search all connections
Abstract ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY WITH THE CHIMERIC MONOCLONAL ANTIBODY INFLIXIMAB IN SEVERE UNDIFFERENTIATED SPONDYLOARTHROPATHY Organization:Rheumatology, Hannov...,Congress:EULAR 2004, Search all connections
Abstract ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY IN REFRACTORY BEHÇET UVEITIS: A SINGLE CENTER EXPERIENCE Organization:Ophtalmology, CHU, L...,Internal Medicine Rh...,Pediatric Rheumatolo...,Congress:EULAR 2013, Search all connections
Abstract ANTI-TUMOR NECROSIS FACTOR-ALPHA DRUGS MODULATE HUMAN ADAM-17 EXPRESSION IN SJÖGREN'S SYNDROME Organization:Department of Intern...,Department of Human ...,Congress:EULAR 2011, Search all connections
Abstract ANTI-TUMOR NECROSIS FACTOR THERAPY MAY INFLUENCE STRUCTURAL PROGRESSION IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS Organization:Copenhagen Center fo...,Medicine, University...,Medicine, Mahidol Un...,Congress:EULAR 2014, Search all connections
Abstract ANTI-TUMOR NECROSIS FACTOR ALPHA THERAPY IS BENEFICAL FOR REFRACTORY TAKAYASU ARTERITIS: A MULTICENTRIC RETROSPECTIVE STUDY FROM TURKEY Organization:Department of Intern...,Department of Intern...,Department of Intern..., Search all connections
Abstract ANTI- TUMOR NECROSIS FACTOR ALPHA KEEPS DENDRITIC CELLS TO PRODUCE INTERFERON-ALPHA FOSTERING THE APPEARANCE OF ANTINUCLEAR ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS Organization:Rheumatology, Societ...,Hôpital Pellegrin,Internal Medicine, T...,Congress:EULAR 2005, Search all connections
Abstract ANTI - TUMOR NECROSIS FACTOR ALPHA (ANTI-TNF) DRUGS IN RHEUMATOID ARTHRITIS: COMPARISON ON DISEASE MANAGEMENT BEFORE AND AFTER THE INTRODUCTION OF THESE BIOLOGICAL DRUGS IN MODENA, ITALY Organization:Rheumatology Unit, U...,Congress:EULAR 2009, Search all connections
Abstract ANTI - TUMOR NECROSIS ALPHA THERAPY IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH A PARTIAL DECREASE OF ALPHA1BETA1 INTEGRIN (VLA-1) EXPRESSING MEMORY TH1 CELLS IN THE PERIPHERAL BLOOD OF TREATMENT RESPONSIVE PATIENTS Organization:Medicine, Chaim Sheb...,Congress:EULAR 2004, Search all connections
Abstract ANALYSIS OF THE IMMUNOGENICITY INDUCED BY TUMOR NECROSIS FACTOR ANTAGONISTS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES. Organization:Rheumatology, Societ...,Immunology, Hospital...,Congress:EULAR 2013, Search all connections
Abstract ANALYSIS OF THE EFFICACY OF TUMOR NECROSIS FACTOR BLOCKERS IN REFRACTORY AUTOINMMUNE UVEITIS Organization:Rheumatology, Societ...,Oftalmology, Hospita...,Congress:EULAR 2009, Search all connections
Abstract ANALYSIS OF OUTCOMES AFTER NON-MEDICAL SWITCHING OF ANTI–TUMOR NECROSIS FACTOR AGENTS Organization:Hospital for Special...,AbbVie Inc., North C...,Medicus Economics, L...,Congress:EULAR 2015, Search all connections
Abstract ANALYSIS OF ASSOCIATIONS BETWEEN TUMOR NECROSIS FACTOR-ALPHA (TNFA -308 G>A, TNFA -238 G>A, TNFA -857 C>T) AND TNF RECEPTORS (TNFRA 36 A>G, TNFRB 676 T>G) GENE POLYMORPHISMS STATUS AND RESPONSIVENESS TO TNF-A BLOCKERS I Organization:Department of Rheuma...,L. Hirszfeld Institu...,Department of Rheuma...,Congress:EULAR 2013, Search all connections
Abstract AFTER DISCONTINUATION OF THE 1ST TUMOR NECROSIS FACTOR INHIBITOR (TNFI), NON-TNFI BIOLOGIC AGENTS HAVE SIMILAR RESPONSES BUT HIGHER SURVIVAL COMPARED TO A 2ND COURSE OF A DIFFERENT TNFI: LONG-TERM PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH RHEUMATO Organization:Rheumatology, Clinic...,4th Internal Medicin...,Congress:EULAR 2017, Search all connections
Abstract ADVERSE SKIN REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS RECIEVING TUMOR NECROSIS FACTOR ALPHA INHIBITOR – AN ANALYSIS OF DATA FROM THE SLOVENIAN BIOLOGICAL REGISTRY Organization:Department of Intern...,Department of Rheuma...,Congress:EULAR 2017, Search all connections
Abstract ADJUSTMENT OF THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TUMOR NECROSIS FACTOR AGENTS Organization:Department of Rheuma...,Congress:EULAR 2006, Search all connections
Abstract ADIPOKINES, TUMOR NECROSIS FACTOR AND ITS RECEPTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS Organization:Rheumatology, Societ...,Interdisciplinary La...,Medical School and H...,Congress:EULAR 2015, Search all connections
Abstract ACTIVATION OF DICKKOPF-1 AND FOCAL ADHESION KINASE PATHWAY BY TUMOR NECROSIS FACTOR-ALPHA ENHANCED MIGRATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS Organization:Catholic University ...,Congress:EULAR 2015, Search all connections
Abstract ACROMEGALY ARTROPATHY: IS THERE SOMETHING MORE BEHIND THE PAIN? A CROSS-SECTIONAL STUDY TO EVALUATE RHEUMATIC DISEASE IN GROWTH HORMONE SECRETING TUMOR PATIENTS Organization:Mauriziano Hospital,...,AOU Città della Salu...,Congress:EULAR 2020, Search all connections
Abstract ABATACEPT (ABT) EQUIVALENT TO ANTI-TUMOR NECROSIS FACTOR A (TNFA) IN TERMS OF JOINT DESTRUCTION INHIBITION: MULTICENTER STUDY OF 107 PATIENTS TREATED FOR 52 WEEKS Organization:Orthopedics, Keiyu O...,Orthopedics, Isesaki...,Rheumatology and Ort...,Congress:EULAR 2013, Search all connections
Abstract A TWO-YEAR LONGITUDINAL STUDY OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS Organization:Centocor, Inc.,Ortho-Clinical Diagn...,PharmaTech Solutions,Congress:EULAR 2008, Search all connections
Abstract A TIME-SHIFTED EFFECT OF TUMOR NECROSIS FACTOR INHIBITORS ON RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: LONG-TERM RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT Organization:Charité – Universitä...,Deutsches Rheuma-For...,Klinikum Bielefeld R...,Congress:EULAR 2021, Search all connections
Abstract A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF INCENTIVE SPIROMETER EXERCISE ON PULMONARY FUNCTIONS OF PATIENTS WITH ANKYLOSING SPONDYLITIS STABILIZED BY TUMOR NECROSIS FACTOR INHIBITOR THERAPY Organization:Division of Rheumato...,Internal Medicine, S...,Congress:EULAR 2012, Search all connections
Abstract A RANDOMIZED CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-α RECEPTOR II FUSION PROTEIN IN JUVENILE IDIOPATHIC ARTHRITIS Organization:Guangzhou Women and ...,Congress:EULAR 2014, Search all connections
Abstract A PHASE I SAFETY STUDY OF COMBINATION TREATMENT WITH PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE I (PEG STNF-RI) AND ANAKINRA (INTERLEUKIN-1 RECEPTOR ANTAGONIST, IL-1RA) IN PATIENTS WITH RHEUMATOID ARTHRITIS Organization:Rheumatology,Florida Arthritis & ...,Daytona Beach, Search all connections
Abstract A PHASE 2 STUDY OF MULTIPLE SUBCUTANEOUS DOSES OF LY2439821, AN ANTI-IL-17 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO POPULATIONS: NAÏVE TO BIOLOGIC THERAPY OR INADEQUATE RESPONDERS TO TUMOR NECROSIS FACTOR ALPHA INHIBITORS Organization:Eli Lilly and Compan...,Pharmanet/i3, Indian...,Congress:EULAR 2012, Search all connections
Abstract A galnt3 gene mutation in two sibs with chronic recurrent multifocal osteomyelitis associated with hyperphosphatemic familial tumoral calcinosis Organization:Clinical Genetics Me...,Congress:EULAR 2018, Search all connections
Abstract A COST-EFFICACY ANALYSIS OF ANTI-TUMOR NECROSIS FACTOR THERAPY IN THE TREATMENT OF RHEUMATOID ARTHRITIS USING RADIOLOGIC OUTCOMES Organization:Centocor Ortho Biote...,Congress:EULAR 2010, Search all connections
Abstract 2-DIMENSIONAL ELECTROPHORESIS PROTEOMIC ANALYSIS FOR THE IDENTIFICATION OF HUMAN NORMAL CHONDROCYTE PROTEOME STIMULATED BY TUMOR NECROSIS FACTOR-α AND INTERLEUKIN-1β Organization:Osteoarticular and A...,Congress:EULAR 2007, Search all connections
Abstract 18FDP-PET/CT FINDING OF SAPHO SYNDROME WHICH SUSPECTED METASTATIC SPINAL TUMORS - FOUR CASE REPORTS- Organization:Othopaedic surgery, ...,Othopaedic surgery, ...,Congress:EULAR 2009, Search all connections
Abstract -383 TUMOR NECROSIS FACTOR RECEPTOR 1 POLYMORPHISM AND ANKYLOSING SPONDYLITIS IN MEXICAN PATIENTS Organization:Unidad de Investigac...,Congress:EULAR 2008, Search all connections
Abstract -383 A/C TUMOR NECROSIS FACTOR RECEPTOR 1 POLYMORPHISM AND SERUM LEVELS OF TNFRI AND TNFRII IN RHEUMATOID ARTHRITIS Organization:Instituto de Investi...,Congress:EULAR 2009, Search all connections
Abstract -308 A/G POLYMORPHISM IN THE TUMOR NECROSIS FACTOR-A GENE INFLUENCES OUTCOME OF ETANERCEPT TREATMENT IN RHEUMATOID ARTHRITIS Organization:Service de Rhumatolo...,Service de Rheumatol...,Hôpital de la Concep..., Search all connections
Abstract Study on influencing factors and survival analysis of patients with malignant tumors treated by music therapy. Congress:ASCO 2019, Search all connections
Abstract Cognitive impairment and treatment effects among gastrointenstinal stromal tumor survivors: Results of a large online survey. Congress:ASCO 2019, Search all connections
Abstract Persistent radiation-induced alopecia in patients with central nervous system tumors and head and neck sarcomas. Congress:ASCO 2019, Search all connections
Abstract Comparison of mortality trends in geriatric and nongeriatric patients with salivary gland tumors. Congress:ASCO 2019, Search all connections
Abstract Competing causes of death in patients with neuroendocrine tumor. Congress:ASCO 2019, Search all connections
Abstract Desmoid tumor (DT) management in dedicated sarcoma medical oncology clinic in a developing country: Lessons learnt. Congress:ASCO 2019, Search all connections
Abstract Prognostic implications of tumor associated macrophages (TAMs) in soft tissue sarcoma. Congress:ASCO 2019, Search all connections
Abstract Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR). Congress:ASCO 2019, Search all connections
Abstract Outcome of patients with refractory malignant peripheral nerve sheath tumors (MPNST) enrolled on phase 2 trials. Congress:ASCO 2019, Search all connections
Abstract Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy. Congress:ASCO 2019, Search all connections
Abstract Work productivity loss in patients with tenosynovial giant cell tumors in the United States. Congress:ASCO 2019, Search all connections
Abstract Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: A retrospective analysis. Congress:ASCO 2019, Search all connections
Abstract Relationship among ETV1 genetic polymorphisms, PFS, and microRNA in gastrointestinal stromal tumors. Congress:ASCO 2019, Search all connections
Abstract Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS). Congress:ASCO 2019, Search all connections
Abstract The long term surgical outcome of spinal giant cell tumor. Congress:ASCO 2019, Search all connections
Abstract Utility of tumor genomic profiling in guiding targeted therapy and referral for clinical trials in the community practice. Congress:ASCO 2019, Search all connections
Abstract Economic impact of post-progression treatment in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously treated with octreotide monotherapy. Congress:ASCO 2019, Search all connections
Abstract Impact of solid tumor brain metastases on end-of-life healthcare utilization. Congress:ASCO 2019, Search all connections
Abstract Implementation and evaluation of video-based tumor board conferencing in Haiti. Congress:ASCO 2019, Search all connections
Abstract Development and feasibility of virtual molecular tumor board. Congress:ASCO 2019, Search all connections
Abstract Quality of life and tumor location in patients with desmoid tumors: Data from the desmoid tumor research foundation natural history study. Congress:ASCO 2019, Search all connections
Abstract Impact of international collaboration utilizing E-consult and E-tumor board in the multidisciplinary management of cancer patients: A study from Mayo Clinic Care Network (MCCN) members. Congress:ASCO 2019, Search all connections
Abstract Inpatient outcome of solid tumor associated tumor lysis syndrome. Congress:ASCO 2019, Search all connections
Abstract Visualizing real-world outcomes through the lens of a molecular tumor board: Persona-typing pancreatic cancers for clinical decision support. Congress:ASCO 2019, Search all connections
Abstract Recovery of symptom burden and functioning for patients with late discharge after an open surgery for GYN tumors. Congress:ASCO 2019, Search all connections
Abstract Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice. Congress:ASCO 2019, Search all connections
Abstract Patient-reported outcomes during hospitalization for patients with late discharge after an open surgery for GYN tumors. Congress:ASCO 2019, Search all connections
Abstract Mutational analysis of >14,000 solid tumor NGS tests from community oncology practices: The Sarah Cannon molecular landscape. Congress:ASCO 2019, Search all connections
Abstract The impact of a digital solution on case discussion time at tumor boards. Congress:ASCO 2019, Search all connections
Abstract The impact of a digital solution on tumor board preparation time for nurse navigators. Congress:ASCO 2019, Search all connections
Abstract Early non-invasive detection of stage Ia lung cancer using circulating tumor DNA methylation haplotypes (ctmDNA) in plasma. Congress:ASCO 2019, Search all connections
Abstract Pulmonary F-18 FDG uptake of non-tumor area in lung cancer patients to provide risk stratification in postoperative acute exacerbation of interstitial lung disease. Congress:ASCO 2019, Search all connections
Abstract DNA Input, sequencing depth, and maximum somatic allele frequency may affect the concordance between blood TMB and tumor TMB. Congress:ASCO 2019, Search all connections
Abstract Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism. Congress:ASCO 2019, Search all connections
Abstract Patient attendance at molecular tumor board: A new means of shared decision making? Congress:ASCO 2019, Search all connections
Abstract Performance and validation of a tumor mutation profiling, based on artificial intelligence annotation, to assist oncology decision making. Congress:ASCO 2019, Search all connections
Abstract Suspected and confirmed germline variants from tumor-only somatic sequencing of 864 gastrointestinal malignancies. Congress:ASCO 2019, Search all connections
Abstract Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types. Congress:ASCO 2019, Search all connections
Abstract Detect and visualize tumor microsatellite instability status from next-generation sequencing data by simulating PCR techniques. Congress:ASCO 2019, Search all connections
Abstract The landscape of POLE/POLD1 mutations in Chinese solid tumor patients. Congress:ASCO 2019, Search all connections
Abstract A novel computational tool for copy number variation detection in targeted circulating tumor DNA. Congress:ASCO 2019, Search all connections
Abstract Procancerous immune cells in primary tumor is associated with breast cancer recurrence. Congress:ASCO 2019, Search all connections
Abstract Low likelihood that potential germline findings identified during somatic tumor testing are evaluated: Room for improvement. Congress:ASCO 2019, Search all connections
Abstract Discussion on several problems between tumor-associated venous thrombosis and driving genes status. Congress:ASCO 2019, Search all connections
Abstract Confirmation of germline variants identified by tumor testing: A population-based study. Congress:ASCO 2019, Search all connections
Abstract Predictive molecular tumor response through circulating DNA (cDNA) measurements and correlation with established prognostic markers in a series of solid tumors treated with multitargeted epigenetic therapy (MTET). Congress:ASCO 2019, Search all connections
Abstract A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614). Congress:ASCO 2019, Search all connections
Abstract Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Congress:ASCO 2019, Search all connections
Abstract Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea: A nationwide population-based, longitudinal study. Congress:ASCO 2019, Search all connections
Abstract MRI based radiomic signature to predict treatment response to intraventricular natural killer (NK) cell infusion therapy for recurrent/refractory pediatric brain tumors. Congress:ASCO 2019, Search all connections
Abstract Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation and tumor xenograft studies. Congress:ASCO 2019, Search all connections
Abstract Genetic relationship between pilar cysts, pilar tumors and pilar carcinomas. Congress:ASCO 2019, Search all connections
Abstract Characterization of mechano-microenvironment of acral melanoma and its potential impact on tumor cell invasion. Congress:ASCO 2019, Search all connections
Abstract Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma. Congress:ASCO 2019, Search all connections
Abstract Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma. Congress:ASCO 2019, Search all connections
Abstract Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (aNSCLC) patients (pts). Congress:ASCO 2019, Search all connections
Abstract A joint model of tumor size dynamics and survival with new lesions in EGFR mutation-positive non-small cell lung cancer patients with treatment of gefitinib or carboplatin and paclitaxel. Congress:ASCO 2019, Search all connections
Abstract Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Clinical implications of monitoring circulating tumor DNA in early- and late-stage non-small cell lung cancer patients. Congress:ASCO 2019, Search all connections
Abstract Development and validation of a deep learning model to assess tumor progression to immunotherapy. Congress:ASCO 2019, Search all connections
Abstract The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations. Congress:ASCO 2019, Search all connections
Abstract Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Clinical importance of long noncoding RNA LINC00460 expression in plasma cell-free tumor RNA in EGFR-mutant adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy. Congress:ASCO 2019, Search all connections
Abstract KMT2C mutation associated with tumor mutational burden in small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients. Congress:ASCO 2019, Search all connections
Abstract Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment. Congress:ASCO 2019, Search all connections
Abstract The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of tumor infiltrating lymphocytes in epithelioid malignant pleural mesothelioma. Congress:ASCO 2019, Search all connections
Abstract Report of four cases of pulmonary malignant tumors treated with SBRT using BODYFIX plus 4D-CBCT image guidance technique. Congress:ASCO 2019, Search all connections
Abstract The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma. Congress:ASCO 2019, Search all connections
Abstract Evaluation of tumor infiltrating lymphocites (TILs) and survival in patients with resected non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Ectopic prolactin production by lung cancer cells as an indicator of aggressive nature of tumors. Congress:ASCO 2019, Search all connections
Abstract Primary tumor location as an important predictor for survival in pulmonary adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Correlation of tumor mutational burden, tumor microenvironment and alterations of driver genes in patients with NSCLC: A retrospective analysis. Congress:ASCO 2019, Search all connections
Abstract Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors. Congress:ASCO 2019, Search all connections
Abstract Distribution and influencing factors of tumor mutational burden in different lymphoma subtypes. Congress:ASCO 2019, Search all connections
Abstract Pattern of rasburicase (RAS) use in community oncology programs and impact on tumor lysis syndrome (TLS) outcomes. Congress:ASCO 2019, Search all connections
Abstract The value of low, fixed, single dose rasburicase in the prevention and treatment of tumor lysis syndrome. Congress:ASCO 2019, Search all connections
Abstract Diagnostic value of cytokeratin-1, survivin and TG expression in circulating tumor cells in the differentiation of benign and malignant thyroid nodules. Congress:ASCO 2019, Search all connections
Abstract Precision oncology for the treatment of salivary gland tumors. Congress:ASCO 2019, Search all connections
Abstract The effect of induction chemotherapy on tumor volume changes in patients with locoregionally advanced nasopharyngeal carcinoma. Congress:ASCO 2019, Search all connections
Abstract A novel mechanism of miRNA-mediated CBX8 associated with tumorigenesis in head and neck squamous cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Selected molecular markers as indicators of clinical profile, tumor characteristics and treatment outcome in squamous cell carcinoma of the larynx. Congress:ASCO 2019, Search all connections
Abstract A Nationwide analysis of mortality trends in geriatric and non-geriatric patients with oral cavity tumors. Congress:ASCO 2019, Search all connections
Abstract The influence of obesity on tumor recurrence in vulvar cancer patients. Congress:ASCO 2019, Search all connections
Abstract Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Congress:ASCO 2019, Search all connections
Abstract Clinicopathological significance and prognostic value of intratumoral and peritumoral lymphocytes in endometrial cancer patients. Congress:ASCO 2019, Search all connections
Abstract The effects of Wnt inhibition on tumor progression and the tumor microenvironment in a syngeneic mouse model of ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract A 3D micro-tumor model capturing tumor heterogeneity of a patient's primary tumor biopsy. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of tumor parameters measured by MRI in cervical cancer patients receiving CCRT. Congress:ASCO 2019, Search all connections
Abstract The value of tumor paramaters and dosimetry on prognostic nomograms for cervical cancer. Congress:ASCO 2019, Search all connections
Abstract Survival differences based on tumor size among stage 1B cervical cancer patients in Louisiana using revised FIGO staging system. Congress:ASCO 2019, Search all connections
Abstract Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC). Congress:ASCO 2019, Search all connections
Abstract Next-generation sequencing of primary prostate cancer tumors to reveal actionable opportunities for clinical management. Congress:ASCO 2019, Search all connections
Abstract PMEPA1 gene isoforms to indicate disease progression in solid tumors. Congress:ASCO 2019, Search all connections
Abstract Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients. Congress:ASCO 2019, Search all connections
Abstract Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants. Congress:ASCO 2019, Search all connections
Abstract Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release. Congress:ASCO 2019, Search all connections
Abstract Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study. Congress:ASCO 2019, Search all connections
Abstract Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). Congress:ASCO 2019, Search all connections
Abstract The clinical features of extragonadal germ cell tumors: A SEER analysis. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors. Congress:ASCO 2019, Search all connections
Abstract Improved outcomes in testicular germ cell tumor patients treated at the referral center in Slovakia in the last decade. Congress:ASCO 2019, Search all connections
Abstract Impact of cannabis (CA) use on chemotherapy (C) treatment and tumor characteristics of patients (pts) with testicular germ cell tumor (TGCT): Experience of the Centre Léon Bérard (CLB). Congress:ASCO 2019, Search all connections
Abstract High DNA damage levels to predict hematologic toxicity in testicular germ cell tumor (TGCT) patients treated with first-line chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Long-term sexual impairment in relationship with metabolic health in testicular germ-cell tumor survivors. Congress:ASCO 2019, Search all connections
Abstract Site, age, and gender distribution of extra-gonadal germ cell tumors in the US from 1973 to 2015. Congress:ASCO 2019, Search all connections
Abstract Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT). Congress:ASCO 2019, Search all connections
Abstract Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT). Congress:ASCO 2019, Search all connections
Abstract A single center experience of the impact of treatment-related toxicity in the clinical outcomes of elderly patients with metastatic germ cell tumors. Congress:ASCO 2019, Search all connections
Abstract Risk factors for renal failure (RF) during high-dose chemotherapy (HDCT) and outcomes for patients (pts) with relapsed germ-cell tumors (rGCT). Congress:ASCO 2019, Search all connections
Abstract Different expression and prognostic implications of PD-L1 in tumor cells and immune cells with the SP263 monoclonal antibody in Chinese urothelial carcinoma patients. Congress:ASCO 2019, Search all connections
Abstract Genomic landscape of circulating tumor (ct)-DNA alterations in patients with penile cancer. Congress:ASCO 2019, Search all connections
Abstract Histology and stage at presentation among patients with rare pancreatic tumors: An exploratory analysis of the SEER database. Congress:ASCO 2019, Search all connections
Abstract Association of pancreatic cancer stem cells with tumor stroma type. Congress:ASCO 2019, Search all connections
Abstract Dynamic assessment of circulating tumor DNA in prediction of response to nab-paclitaxel-based first-line chemotherapy in metastatic pancreatic cancer. Congress:ASCO 2019, Search all connections
Abstract Transducer array layout optimization for the treatment of pancreatic cancer using Tumor Treating Fields (TTFields) in the phase 3 PANOVA-3 trial. Congress:ASCO 2019, Search all connections
Abstract Effect of tumor cell-derived debris and IgG on metastasis of pancreatic cancer and inflammation through tumor-associated macrophages. Congress:ASCO 2019, Search all connections
Abstract Significant neutrophil accumulation, IL-18 deposition, and active inflammasome in tumor regions of human pancreatic ductal adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Retrospective determination of the correlation between the distance of tumor manifestation to peripancreatic arteries and overall survival in primary resected pancreatic ductal adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of lymph node positivity and number of lymph nodes required for accurate staging of pancreatic neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Sequential assessments of KRAS-mutated circulating tumor DNA in longitudinal monitoring enable the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Congress:ASCO 2019, Search all connections
Abstract Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET). Congress:ASCO 2019, Search all connections
Abstract Antitumor efficacy of M3814 as a radiation sensitizer in neuroendocrine tumor (NET) preclinical models. Congress:ASCO 2019, Search all connections
Abstract Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA analysis of neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Geographic and demographic disparities in neuroendocrine tumors (NETs): A population-based study. Congress:ASCO 2019, Search all connections
Abstract Monitoring of neuroendocrine tumors in elderly patients in the Brittany region. Congress:ASCO 2019, Search all connections
Abstract First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval. Congress:ASCO 2019, Search all connections
Abstract Methylation and mRNA analysis of differential genes between primary tumor and liver metastasis in pancreatic neuroendocrine neoplasm. Congress:ASCO 2019, Search all connections
Abstract Evaluation of Ki67 and other predictors of survival in metastatic neuroendocrine tumor (NET) to the liver treated with Y90 radioembolization. Congress:ASCO 2019, Search all connections
Abstract Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC. Congress:ASCO 2019, Search all connections
Abstract Characterization of tumor mutation burden, PD-L1 and hepatitis B virus in Chinese hepatocellular carcinoma patients. Congress:ASCO 2019, Search all connections
Abstract Integrated multi-omic analysis to reveal comprehensive tumor heterogeneity and novel immunophenotypic classification in primary liver cancer. Congress:ASCO 2019, Search all connections
Abstract The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo. Congress:ASCO 2019, Search all connections
Abstract Mutation profiles in circulating tumor DNA (ctDNA) to predict the efficacy of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC). Congress:ASCO 2019, Search all connections
Abstract Hepatocellular carcinoma with tumor thrombus in portal vein branch: Transarterial chemoembolization combined with Iodine125 brachytherapy versus transarterial chemoembolization combined with sorafenib. Congress:ASCO 2019, Search all connections
Abstract Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade. Congress:ASCO 2019, Search all connections
Abstract FOXO1, an AKT downstream substrate, plays a role as tumor suppressor in HCC pathogenesis. Congress:ASCO 2019, Search all connections
Abstract A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Molecular pathway activation-based analysis for personalized prescription of tyrosine kinase inhibitors for advanced solid tumor patients. Congress:ASCO 2019, Search all connections
Abstract An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors. Congress:ASCO 2019, Search all connections
Abstract Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced hepatocellular carcinoma. Congress:ASCO 2019, Search all connections
Abstract Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA). Congress:ASCO 2019, Search all connections
Abstract Development of radiotherapeutic rhenium-188 liposomes in alginate microspheres (Rhe-LAMs) for treatment of liver tumors and technetium-99m liposomes in alginate microspheres (Tech-LAMs) for image-guided treatment planning. Congress:ASCO 2019, Search all connections
Abstract Comparison of tumor characteristics and survival between esophageal and other gastroenteropancreatic neuroendocrine neoplasms. Congress:ASCO 2019, Search all connections
Abstract Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience. Congress:ASCO 2019, Search all connections
Abstract Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Apatinib inhibits tumor progression and promotes antitumor efficacy of cytotoxic drugs in esophageal squamous cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Immune biomarker expression in the tumor microenvironment in Chinese patients with esophageal squamous cell carcinoma was explored. Congress:ASCO 2019, Search all connections
Abstract tPA and PAI-1 in malignant tissues of gastric adenocarcinoma can be tumor-associated. Congress:ASCO 2019, Search all connections
Abstract Expression of CD44 and CD133 in tumor сells of metastatic and non-metastatic gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt pathway signaling, on gene expression and antitumor activity in colorectal cancer (CRC) models. Congress:ASCO 2019, Search all connections
Abstract Role of tropomyosin 4 gene misregulation in colon epithelial cell tumorigenesis. Congress:ASCO 2019, Search all connections
Abstract Association between primary tumor site, perioperative CEA ratio, smoking status, and overall survival in patients with colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology. Congress:ASCO 2019, Search all connections
Abstract Prevalence of DNA damage response and repair, cellular signaling, tumor suppressor, and immune checkpoint gene mutations in gastrointestinal cancers. Congress:ASCO 2019, Search all connections
Abstract Metastatic pattern and tumor sidedness in colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Radiomic profiles via machine learning to predict response, overall survival, and KRAS status in metastatic colorectal tumors treated with FOLFOX/bevacizumab/hydroxychloroquine. Congress:ASCO 2019, Search all connections
Abstract An improved method for detection of methylated circulating tumor DNA in colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Sensitive detection of microsatellite instability in tumors and liquid biopsies using nuclease-based enrichment. Congress:ASCO 2019, Search all connections
Abstract Analytical and clinical validation of a novel amplicon-based NGS assay for evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Congress:ASCO 2019, Search all connections
Abstract DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA-based mutational landscape of advanced colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study. Congress:ASCO 2019, Search all connections
Abstract Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Somatic mutations in non-small cell lung cancer and their correlation with overall survival, tumor mutation burden, and programmed-death cell ligand-1 (PD-L1) status. Congress:ASCO 2019, Search all connections
Abstract Therapy alteration of solid tumors based on FoundationOne comprehensive genome profiling assay. Congress:ASCO 2019, Search all connections
Abstract Multiplatform molecular profiling: Observational study to determine the effect of treatment selection in advanced or refractory metastatic solid tumors. Congress:ASCO 2019, Search all connections
Abstract Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors. Congress:ASCO 2019, Search all connections
Abstract Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract A phase I study investigating the absorption, metabolism, and excretion of [14C] anlotinib in patients with advanced refractory solid tumors. Congress:ASCO 2019, Search all connections
Abstract Biofabricated tumor microenvironments for studying colorectal cancer in vitro and in vivo. Congress:ASCO 2019, Search all connections
Abstract Clinical analysis of cancer associated venous thromboembolism in hospitalized patients with malignant solid tumors in real-world practices. Congress:ASCO 2019, Search all connections
Abstract A general approach to optimizing tumor treating fields therapy. Congress:ASCO 2019, Search all connections
Abstract Thyrointegrin αvβ3 nano targeted delivery of chemotherapy into solid tumors and its microenvironment. Congress:ASCO 2019, Search all connections
Abstract Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform. Congress:ASCO 2019, Search all connections
Abstract Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations. Congress:ASCO 2019, Search all connections
Abstract Integrating CRISPR screening with tumor genomic analyses to identify therapeutic targets in hepatocellular carcinomas (HCC) independent of P53. Congress:ASCO 2019, Search all connections
Abstract Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields. Congress:ASCO 2019, Search all connections
Abstract Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice. Congress:ASCO 2019, Search all connections
Abstract A preliminary single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors: Personal precision oncology clinic and genetic diagnostics, Brazil. Congress:ASCO 2019, Search all connections
Abstract NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Notch family gene mutations associate with high tumor mutational burden in diverse cancers. Congress:ASCO 2019, Search all connections
Abstract Analytical validation of the Oncomine Pan-Cancer Cell-Free Assay in a CLIA- and CAP-regulated laboratory for detection of solid tumor-derived variants in blood plasma. Congress:ASCO 2019, Search all connections
Abstract Quantitative image profiling of the tumor microenvironment on double stained immunohistochemistry images using deep learning. Congress:ASCO 2019, Search all connections
Abstract Antitumor immune response induced by NBTXR3 activated by radiotherapy. Congress:ASCO 2019, Search all connections
Abstract Concurrent targeted resequencing for translocations and mutations in tumor samples. Congress:ASCO 2019, Search all connections
Abstract Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study). Congress:ASCO 2019, Search all connections
Abstract Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence. Congress:ASCO 2019, Search all connections
Abstract Genetic mutation analysis of plasma circulating tumor DNA by ultra-deep sequencing in breast benign lesions and cancers. Congress:ASCO 2019, Search all connections
Abstract Dynamic change of PD-L1 expression on circulating tumor cells in advanced breast cancer undergoing PD-1 blockade therapy. Congress:ASCO 2019, Search all connections
Abstract Clinical significance of circulating tumor cells identified by cell-surface vimentin in pancreatic cancer. Congress:ASCO 2019, Search all connections
Abstract The utility of circulating tumor DNA analysis to identify BRAF mutations in malignant melanoma. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA (ctDNA) mutation and epigenomic patterns in early-stage lung cancer patients and its utility in identifying patients at high risk for early recurrence. Congress:ASCO 2019, Search all connections
Abstract Real-world application of liquid biopsy in gastrointestinal tumors: Experience from a comprehensive cancer center. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA molecular profiling in rare cancer patients from the MASTER KEY Project. Congress:ASCO 2019, Search all connections
Abstract CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR. Congress:ASCO 2019, Search all connections
Abstract Circulating cell-free tumor DNA chromosomal instability and circulating tumor cells as tools to predict microvascular invasion of hepatocellular carcinoma. Congress:ASCO 2019, Search all connections
Abstract Systemic immune-inflammation index to predict prognosis of elderly patients with newly diagnosed solid tumors. Congress:ASCO 2019, Search all connections
Abstract A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells. Congress:ASCO 2019, Search all connections
Abstract Detection of low abundant mutants from circulating tumor DNA of plasma, pleural effusion, and cerebrospinal fluid of lung cancer patients using a novel mutant-capture enrichment approach. Congress:ASCO 2019, Search all connections
Abstract A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies. Congress:ASCO 2019, Search all connections
Abstract Clinical assessment of tumor angiogenesis and its predictive value for chemotherapy responses of colorectal metastatic hepatic tumors. Congress:ASCO 2019, Search all connections
Abstract High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma. Congress:ASCO 2019, Search all connections
Abstract Role of metabolic reprogramming toward fatty acid oxidation on tumor lymph node metastasis. Congress:ASCO 2019, Search all connections
Abstract Genes copy number variation in tumor cells of patients with metastatic and non-metastatic lung adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity. Congress:ASCO 2019, Search all connections
Abstract Comparison of biomarkers among 34,855 GI cancer samples show heterogeneity of tumor types. Congress:ASCO 2019, Search all connections
Abstract Immune checkpoint inhibitor response in tumors with LRP1B variants. Congress:ASCO 2019, Search all connections
Abstract Frequency of discordance in programmed death ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: A systematic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Development of a PD-L1 multiplex immunofluorescence assay with advanced visual analysis for understanding the tumor microenvironment. Congress:ASCO 2019, Search all connections
Abstract Utilization of novel highly multiplexed immunofluorescence microscopy technology to understand immunological tumor microenvironments in small cell lung carcinoma patients receiving combination PD-L1 and PARP inhibition therapy. Congress:ASCO 2019, Search all connections
Abstract Biomarkers of Chinese advanced cancer patients based on real-world data: Actionable genomic alterations and tumor mutational burden. Congress:ASCO 2019, Search all connections
Abstract Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract A landscape analysis of immunotherapy-related biomarkers across solid tumors. Congress:ASCO 2019, Search all connections
Abstract Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC). Congress:ASCO 2019, Search all connections
Abstract Defining tissue requirements for a reliable detection of tumor mutational burden (TMB) in clinical FFPE samples. Congress:ASCO 2019, Search all connections
Abstract Cancer-testis gene-expression features in various tumors. Congress:ASCO 2019, Search all connections
Abstract Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Interleukin-2 boosts local and abscopal antitumor effect of radiotherapy combined with anti-PD-1: A translational research from clinical radio-memory effect. Congress:ASCO 2019, Search all connections
Abstract A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI). Congress:ASCO 2019, Search all connections
Abstract Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity. Congress:ASCO 2019, Search all connections
Abstract Reovirus strain R-92 in in vitro generation of tumor-specific T-lymphocytes. Congress:ASCO 2019, Search all connections
Abstract Spatially-resolved, multiplexed quantification of protein and mRNA distribution and abundance in colorectal cancer tumor microenvironment with multiple modalities of NanoString GeoMx Digital Spatial Profiler. Congress:ASCO 2019, Search all connections
Abstract MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment. Congress:ASCO 2019, Search all connections
Abstract Microsatellite instability assessment of FFPE tumor samples through targeted next-generation sequencing. Congress:ASCO 2019, Search all connections
Abstract Modified ketogenic diet in solid tumors: A Veteran Affairs Pittsburgh Healthcare System case series. Congress:ASCO 2019, Search all connections
Abstract The interplay of adiposity, metabolic factors, and tumor infiltrating lymphocytes in an East Asian breast cancer cohort. Congress:ASCO 2019, Search all connections
Abstract Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer. Congress:ASCO 2019, Search all connections
Abstract Electron microscopic characteristic of local immune processes during regression of developed experimental tumors under the influence of magnetite nanoparticles. Congress:ASCO 2019, Search all connections
Abstract Anti-HER2/Neu antibody therapy can reduce the immunosuppressive activity of MDSCs in breast tumor model. Congress:ASCO 2019, Search all connections
Abstract Characterization of a patient-specific T-cell and tumor cell coculture model of immuno-cytotoxicity in colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract An effective and accurate algorithm for measuring the tumor mutation burden of cancer patients plasma. Congress:ASCO 2019, Search all connections
Abstract Outcomes and toxicities in sarcopenic patients with metastatic solid tumors treated with check point inhibitors. Congress:ASCO 2019, Search all connections
Abstract Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs). Congress:ASCO 2019, Search all connections
Abstract T cell receptor β-chain repertoire analysis to reveal potential predictive biomarker for the use of immune checkpoint blockade in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with advanced solid tumors treated with PD-1 inhibitors. Congress:ASCO 2019, Search all connections
Abstract Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Clinical implication of monitoring PD-L1+ circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy. Congress:ASCO 2019, Search all connections
Abstract Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients. Congress:ASCO 2019, Search all connections
Abstract Correlation between peripheral CD8+PD-1+ T cells diversity, tumor mutation burden (TMB) and T cell clones with anti-PD-1 antibody treatment of lung cancer patients: TCR repertoire as a novel predictive biomarker. Congress:ASCO 2019, Search all connections
Abstract Addition of immunotherapy in adjuvant setting could be a promising avenue of colorectal cancer (CRC) treatment, especially in patients with higher levels of programmed cell death ligand-1 (PD-L1) positive circulating epithelial tumor cells (CETC) after neoadjuvant chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? Congress:ASCO 2019, Search all connections
Abstract PD-L1 expression on circulating tumor cells and prognosis of breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract Effect of radiotherapy on the residual circulating epithelial tumor cells (CETCs) and their programmed cell death ligand 1 (PD-L1) status in breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response. Congress:ASCO 2019, Search all connections
Abstract Quantification of activated and exhausted immune cell populations and simultaneous characterization of circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy. Congress:ASCO 2019, Search all connections
Abstract Effect on anti-tumor immunity and long-term memory CD8+ T-cell generation with a novel, allogeneic cell-based, Gp96-Ig/OX40L cancer vaccine. Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer. Congress:ASCO 2019, Search all connections
Abstract Treatment with tumor-infiltrating lymphocytes in the changing treatment landscape of metastatic melanoma. Congress:ASCO 2019, Search all connections
Abstract Phase Ia clinical trial of adoptively transferring peripheral blood-derived cytotoxic T lymphocytes targeting individual neo-antigens to treat patients with advanced solid tumor. Congress:ASCO 2019, Search all connections
Abstract Long-term survival in patients (pts) with locally advanced or disseminated malignant melanoma (MM) or renal cell carcinoma (RCC), treated with tag-7 gene-modified (GMV) tumor cells: A phase II trial. Congress:ASCO 2019, Search all connections
Abstract A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of PD-1 blockade-activated multiple antigen specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials. Congress:ASCO 2019, Search all connections
Abstract Comparison of in vitro antitumor activity between SB3 (trastuzumab biosimilar, Ontruzant) and Herceptin combined with an antibody for subdomain II of HER2 in HER2-positive cancer cells. Congress:ASCO 2019, Search all connections
Abstract Potent targeting of B cell lymphoma and plasma cell tumors by a tetravalent, Fc-engineered antibody directed against the glycoantigen CD75s. Congress:ASCO 2019, Search all connections
Abstract The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases. Congress:ASCO 2019, Search all connections
Abstract Molecular profiling using the 92-gene assay for tumor classification of brain metastases. Congress:ASCO 2019, Search all connections
Abstract Radiomics-based identification of peritumoral infiltration in de novo glioblastoma imaging presents targets amenable for potential targeted extended resection: A neurosurgical survey. Congress:ASCO 2019, Search all connections
Abstract DDR1 may be a good biomarker for brain tumors. Congress:ASCO 2019, Search all connections
Abstract Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors. Congress:ASCO 2019, Search all connections
Abstract Mutations of H3.3 and H3.1 in a large cohort of glioma tumors. Congress:ASCO 2019, Search all connections
Abstract Factors associated with delays in diagnosis of pediatric, adolescent and young adult patients with central nervous system tumors. Congress:ASCO 2019, Search all connections
Abstract Safety and pharmacokinetics of BXQ-350 in a phase 1a and 1b trial of solid tumors and high-grade glioma. Congress:ASCO 2019, Search all connections
Abstract Intracerebral immunotherapy for brain tumors. Congress:ASCO 2019, Search all connections
Abstract Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality. Congress:ASCO 2019, Search all connections
Abstract The use of metformin to enhance radiation effects on M1 macrophage subtype polarization in bone marrow-derived macrophage in glioblastoma tumor environment. Congress:ASCO 2019, Search all connections
Abstract Tracking the tumor evolution of patients with recurrence of ipsilateral breast tumor. Congress:ASCO 2019, Search all connections
Abstract Hybrid capture-based genomic profiling of circulating tumor DNA from patients with metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Congress:ASCO 2019, Search all connections
Abstract FDG uptake to reflect NLR and expression levels of TILs and PD-L1 in patients with primary breast cancer: Tumor inflammation and immunity. Congress:ASCO 2019, Search all connections
Abstract The diagnostic accuracy of 12-point core biopsy of a tumor bed compared to the study of surgically obtained breast tissue in patients with locally advanced triple-negative or HER2-positive breast cancer after neoadjuvant systemic and targeted therapy. Congress:ASCO 2019, Search all connections
Abstract Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer. Congress:ASCO 2019, Search all connections
Abstract Serial circulating tumor DNA analysis indicating the efficacy and prognosis of neoadjuvant chemotherapy for locally advanced breast cancer. Congress:ASCO 2019, Search all connections
Abstract The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). Congress:ASCO 2019, Search all connections
Abstract Correlation between TopIIα and ki-67 expression in tumors of luminal, primary operable breast cancer without HER2/neu overexpression in postmenopausal women as a prognostic factor. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor cells in patients with locally advanced breast cancer in evaluation of antitumor treatment efficacy. Congress:ASCO 2019, Search all connections
Abstract Clinical relevance of 21-gene recurrence score with lymph node involvement in HR+HER2- early breast cancer: A tumor size-match paired cohort study. Congress:ASCO 2019, Search all connections
Abstract Using tumor genomic profile testing and comorbidity level to personalize chemotherapy decisions among older patients with early-stage breast cancer. Congress:ASCO 2019, Search all connections
Abstract A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract BRCA1 tumor expression and clinical outcome in Uruguayan breast cancer patients diagnosed before the age of 40 years. Congress:ASCO 2019, Search all connections
Abstract Learning from best scalp cooling practices in a registry: Differences in results from n>7000 patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Solitary fibrous tumor: A Brazilian cohort analysis. Congress:ASCO 2019, Search all connections
Abstract Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease. Congress:ASCO 2019, Search all connections
Abstract Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR). Congress:ASCO 2019, Search all connections
Abstract Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors. Congress:ASCO 2019, Search all connections
Abstract Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT). Congress:ASCO 2019, Search all connections
Abstract Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas. Congress:ASCO 2019, Search all connections
Abstract Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies. Congress:ASCO 2019, Search all connections
Abstract Identification of genomic alterations by circulating tumor DNA in leiomyosarcoma: A molecular analysis of 73 patients. Congress:ASCO 2019, Search all connections
Abstract Racial disparity in incidence and survival for gastrointestinal stromal tumors (GIST): An analysis of SEER database. Congress:ASCO 2019, Search all connections
Abstract Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST. Congress:ASCO 2019, Search all connections
Abstract Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. Congress:ASCO 2019, Search all connections
Abstract Neurofibromatosis 1 (NF1) and gastrointestinal stromal tumors (GISTs): Five-year experience from a regional center in United Kingdom. Congress:ASCO 2019, Search all connections
Abstract Clinical characterization of patients with SDHC epimutation in gastrointestinal stromal tumors. Congress:ASCO 2019, Search all connections
Abstract Correlation of imatinib plasma trough concentrations with adverse reaction in Chinese gastrointestinal stromal tumors patients. Congress:ASCO 2019, Search all connections
Abstract Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy. Congress:ASCO 2019, Search all connections
Abstract A Prospective blinded study of 1000 cases analyzing the role of artificial intelligence: Watson for oncology and change in decision making of a Multidisciplinary Tumor Board (MDT) from a tertiary care cancer center. Congress:ASCO 2019, Search all connections
Abstract Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians. Congress:ASCO 2019, Search all connections
Abstract Blood-based genomic profiling of circulating tumor DNA from patients with advanced biliary tract cancer. Congress:ASCO 2019, Search all connections
Abstract Relationship of liver cancer with LRP1B or TP53 mutation and tumor mutation burden and survival. Congress:ASCO 2019, Search all connections
Abstract Rare tumor with matched germline whole exome sequencing to identify somatic and inherited variants of clinical significance. Congress:ASCO 2019, Search all connections
Abstract AcSé-ESMART: “European Proof of Concept Therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory Tumors in children and adolescents” –ARM D: Olaparib and Irinotecan. Congress:ASCO 2019, Search all connections
Abstract Late toxicities, especially second malignancies, with GWAS analysis in hepatoblastoma cases treated in the Japanese study group for pediatric liver tumor protocol-2. Congress:ASCO 2019, Search all connections
Abstract A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. Congress:ASCO 2019, Search all connections
Abstract Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Congress:ASCO 2019, Search all connections
Abstract A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). Congress:ASCO 2019, Search all connections
Abstract Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). Congress:ASCO 2019, Search all connections
Abstract Medical oncologists’ experience with returning molecular tumor profiling to patients. Congress:ASCO 2019, Search all connections
Abstract Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%. Congress:ASCO 2019, Search all connections
Abstract DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC). Congress:ASCO 2019, Search all connections
Abstract Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes. Congress:ASCO 2019, Search all connections
Abstract DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC). Congress:ASCO 2019, Search all connections
Abstract Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs). Congress:ASCO 2019, Search all connections
Abstract Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis. Congress:ASCO 2019, Search all connections
Abstract First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Anti-EGFR target therapy in advanced thymic epithelial tumors. Congress:ASCO 2019, Search all connections
Abstract Clinical application of circulating cell-free DNA for monitoring the biological course of thymic epithelial tumors. Congress:ASCO 2019, Search all connections
Abstract Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial. Congress:ASCO 2019, Search all connections
Abstract Immune landscape of the tumor microenvironment to predict prognosis and DNA mutations in patients with lung adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract Alteration in tumor immune microenvironment after chemo-radiotherapy for locally advanced non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence. Congress:ASCO 2019, Search all connections
Abstract Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients. Congress:ASCO 2019, Search all connections
Abstract Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma. Congress:ASCO 2019, Search all connections
Abstract Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin lymphoma. Congress:ASCO 2019, Search all connections
Abstract Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Congress:ASCO 2019, Search all connections
Abstract Prognostic impact of baseline circulating tumor cells (CTCs) detected by the isolation by size of epithelial tumor cells (ISET) in locally advanced head and neck squamous cell carcinoma (LAHNSCC): Results of a prospective study. Congress:ASCO 2019, Search all connections
Abstract COX-2 expression and mesenchymal-transition status on circulating tumor cells to predict survival in patients with nasopharyngeal carcinoma: A prospective analysis. Congress:ASCO 2019, Search all connections
Abstract Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Metformin treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients induces an anti-tumorigenic immune response. Congress:ASCO 2019, Search all connections
Abstract Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC. Congress:ASCO 2019, Search all connections
Abstract Safety and antitumor activity of accelerator-based boron neutron capture therapy in patients with inoperable recurrent and locally advanced head and neck cancer: A phase II study. Congress:ASCO 2019, Search all connections
Abstract Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract T cell trafficking within the peritoneal tumor environment and ovarian cancer progression. Congress:ASCO 2019, Search all connections
Abstract BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. Congress:ASCO 2019, Search all connections
Abstract DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. Congress:ASCO 2019, Search all connections
Abstract Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors. Congress:ASCO 2019, Search all connections
Abstract An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors. Congress:ASCO 2019, Search all connections
Abstract The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration Medical Centers (VAMCs). Congress:ASCO 2019, Search all connections
Abstract Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress. Congress:ASCO 2019, Search all connections
Abstract A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer. Congress:ASCO 2019, Search all connections
Abstract AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone. Congress:ASCO 2019, Search all connections
Abstract Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA). Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC). Congress:ASCO 2019, Search all connections
Abstract Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Comparative genomic profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111 patients (Pts) with metastatic clear cell renal cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). Congress:ASCO 2019, Search all connections
Abstract Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). Congress:ASCO 2019, Search all connections
Abstract Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY). Congress:ASCO 2019, Search all connections
Abstract A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. Congress:ASCO 2019, Search all connections
Abstract Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx). Congress:ASCO 2019, Search all connections
Abstract Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Congress:ASCO 2019, Search all connections
Abstract Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients. Congress:ASCO 2019, Search all connections
Abstract Molecular profile of ampulla of vater carcinoma (AVC): A rare tumor type with meaningful molecular alterations. Congress:ASCO 2019, Search all connections
Abstract Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Antitumor efficacy of concurrent everolimus with hepatic transarterial bland embolization (evero-embo) in patients with metastatic well differentiated neuroendocrine tumor (NET). Congress:ASCO 2019, Search all connections
Abstract Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Blood-based next-generation sequencing analysis of neuroendocrine tumors. Congress:ASCO 2019, Search all connections
Abstract Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib. Congress:ASCO 2019, Search all connections
Abstract Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). Congress:ASCO 2019, Search all connections
Abstract The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE). Congress:ASCO 2019, Search all connections
Abstract Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE). Congress:ASCO 2019, Search all connections
Abstract A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results. Congress:ASCO 2019, Search all connections
Abstract Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study). Congress:ASCO 2019, Search all connections
Abstract Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). Congress:ASCO 2019, Search all connections
Abstract Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). Congress:ASCO 2019, Search all connections
Abstract A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma. Congress:ASCO 2019, Search all connections
Abstract Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial. Congress:ASCO 2019, Search all connections
Abstract A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC). Congress:ASCO 2019, Search all connections
Abstract Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing. Congress:ASCO 2019, Search all connections
Abstract Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). Congress:ASCO 2019, Search all connections
Abstract Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients. Congress:ASCO 2019, Search all connections
Abstract Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers. Congress:ASCO 2019, Search all connections
Abstract Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs). Congress:ASCO 2019, Search all connections
Abstract Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients. Congress:ASCO 2019, Search all connections
Abstract Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade. Congress:ASCO 2019, Search all connections
Abstract Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Prospective observational study for treatment resistance-related gene screening using plasma circulating tumor DNA in the third generation EGFR TKI osimertinib therapy elucidator. Congress:ASCO 2019, Search all connections
Abstract A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer. Congress:ASCO 2019, Search all connections
Abstract SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors. Congress:ASCO 2019, Search all connections
Abstract Trial in progress abstract phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I open label study evaluating VT1021 in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. Congress:ASCO 2019, Search all connections
Abstract TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA. Congress:ASCO 2019, Search all connections
Abstract A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma. Congress:ASCO 2019, Search all connections
Abstract Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. Congress:ASCO 2019, Search all connections
Abstract A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701). Congress:ASCO 2019, Search all connections
Abstract A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Congress:ASCO 2019, Search all connections
Abstract A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC). Congress:ASCO 2019, Search all connections
Abstract First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results. Congress:ASCO 2019, Search all connections
Abstract First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 PET/CT. Congress:ASCO 2019, Search all connections
Abstract Machine learning algorithm analysis using a commercial 592-gene NGS panel to accurately predict tumor lineage for carcinoma of unknown primary (CUP). Congress:ASCO 2019, Search all connections
Abstract Transcriptome-based cancer type prediction for tumors of unknown origin. Congress:ASCO 2019, Search all connections
Abstract A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data. Congress:ASCO 2019, Search all connections
Abstract Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100. Congress:ASCO 2019, Search all connections
Abstract Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program. Congress:ASCO 2019, Search all connections
Abstract Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. Congress:ASCO 2019, Search all connections
Abstract Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer. Congress:ASCO 2019, Search all connections
Abstract Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. Congress:ASCO 2019, Search all connections
Abstract A phase I study evaluating COM701 in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort. Congress:ASCO 2019, Search all connections
Abstract Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity. Congress:ASCO 2019, Search all connections
Abstract Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)? Congress:ASCO 2019, Search all connections
Abstract A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors. Congress:ASCO 2019, Search all connections
Abstract SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. Congress:ASCO 2019, Search all connections
Abstract An open label, multicenter, phase 1b/2 study of rebastinib (DCC‑2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors. Congress:ASCO 2019, Search all connections
Abstract A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE). Congress:ASCO 2019, Search all connections
Abstract The dynamic detection of drug area under curve (AUC) guides clinical usage of docetaxel in solid tumors. Congress:ASCO 2019, Search all connections
Abstract An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study. Congress:ASCO 2019, Search all connections
Abstract Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. Congress:ASCO 2019, Search all connections
Abstract PDX validation of a 3D microtumor platform. Congress:ASCO 2019, Search all connections
Abstract A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy. Congress:ASCO 2019, Search all connections
Abstract Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities. Congress:ASCO 2019, Search all connections
Abstract JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect. Congress:ASCO 2019, Search all connections
Abstract Effect of subcutaneous multi-peptide active antigen-specific immunotherapy at lymph nodes and tumor sites on clinical outcomes in progressive tumors. Congress:ASCO 2019, Search all connections
Abstract Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. Congress:ASCO 2019, Search all connections
Abstract Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors. Congress:ASCO 2019, Search all connections
Abstract Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction. Congress:ASCO 2019, Search all connections
Abstract A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues. Congress:ASCO 2019, Search all connections
Abstract Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. Congress:ASCO 2019, Search all connections
Abstract Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines. Congress:ASCO 2019, Search all connections
Abstract Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis. Congress:ASCO 2019, Search all connections
Abstract Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. Congress:ASCO 2019, Search all connections
Abstract Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Congress:ASCO 2019, Search all connections
Abstract Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis. Congress:ASCO 2019, Search all connections
Abstract Pan-tumor prognostic value of multiple immune protein expressions. Congress:ASCO 2019, Search all connections
Abstract Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021). Congress:ASCO 2019, Search all connections
Abstract Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Immune profiling of tumor-infiltrating T cells using mass cytometry. Congress:ASCO 2019, Search all connections
Abstract CD8+ T cells in tumor parenchyma and stroma by image analysis (IA) and gene expression profiling (GEP): Potential biomarkers for immuno-oncology (I-O) therapy. Congress:ASCO 2019, Search all connections
Abstract Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts). Congress:ASCO 2019, Search all connections
Abstract Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China. Congress:ASCO 2019, Search all connections
Abstract AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies. Congress:ASCO 2019, Search all connections
Abstract First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Association of an inflammatory gene signature with CD8 expression by immunohistochemistry (IHC) in multiple tumor types. Congress:ASCO 2019, Search all connections
Abstract Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC). Congress:ASCO 2019, Search all connections
Abstract Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. Congress:ASCO 2019, Search all connections
Abstract Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. Congress:ASCO 2019, Search all connections
Abstract Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs). Congress:ASCO 2019, Search all connections
Abstract Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study. Congress:ASCO 2019, Search all connections
Abstract Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract CD4+ T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy. Congress:ASCO 2019, Search all connections
Abstract Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease. Congress:ASCO 2019, Search all connections
Abstract Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy. Congress:ASCO 2019, Search all connections
Abstract Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P). Congress:ASCO 2019, Search all connections
Abstract Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain. Congress:ASCO 2019, Search all connections
Abstract Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD). Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Congress:ASCO 2019, Search all connections
Abstract A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas. Congress:ASCO 2019, Search all connections
Abstract A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT). Congress:ASCO 2019, Search all connections
Abstract Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma. Congress:ASCO 2019, Search all connections
Abstract Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma. Congress:ASCO 2019, Search all connections
Abstract Study of tumor infiltrating immune CELLS and vasculature in human gliomas: Differences in IDH1/2 mutant versus IDH1/2WT tumors. Congress:ASCO 2019, Search all connections
Abstract Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma. Congress:ASCO 2019, Search all connections
Abstract Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Congress:ASCO 2019, Search all connections
Abstract KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor response of oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC). Congress:ASCO 2019, Search all connections
Abstract Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. Congress:ASCO 2019, Search all connections
Abstract On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Congress:ASCO 2019, Search all connections
Abstract No relationship of axillary total tumor load (TTL) by PCR (OSNA) in early breast cancer and local and distant clinical outcomes. Congress:ASCO 2019, Search all connections
Abstract Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics. Congress:ASCO 2019, Search all connections
Abstract Measuring on-treatment genome-wide tumor copy number alterations in cell-free DNA (cfDNA) in plasma is highly prognostic in metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB). Congress:ASCO 2019, Search all connections
Abstract AL101 mediated tumor inhibition in notch-altered TNBC PDX models. Congress:ASCO 2019, Search all connections
Abstract Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. Congress:ASCO 2019, Search all connections
Abstract Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance). Congress:ASCO 2019, Search all connections
Abstract Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D). Congress:ASCO 2019, Search all connections
Abstract Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). Congress:ASCO 2019, Search all connections
Abstract ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST). Congress:ASCO 2019, Search all connections
Abstract A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor(GIST). Congress:ASCO 2019, Search all connections
Abstract Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa). Congress:ASCO 2019, Search all connections
Abstract Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. Congress:ASCO 2019, Search all connections
Abstract Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies. Congress:ASCO 2019, Search all connections
Abstract Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Congress:ASCO 2019, Search all connections
Abstract Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Circulating PD-L1-exosomes to monitor tumor response in melanoma patients. Congress:ASCO 2019, Search all connections
Abstract Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience. Congress:ASCO 2019, Search all connections
Abstract Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). Congress:ASCO 2019, Search all connections
Abstract Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2019, Search all connections
Abstract Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer). Congress:ASCO 2019, Search all connections
Abstract Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients. Congress:ASCO 2019, Search all connections
Abstract CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072. Congress:ASCO 2019, Search all connections
Abstract A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Primary analysis of Japan Clinical Oncology Group study JCOG1006. Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Congress:ASCO 2019, Search all connections
Abstract A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC). Congress:ASCO 2019, Search all connections
Abstract Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR). Congress:ASCO 2019, Search all connections
Abstract Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Congress:ASCO 2019, Search all connections
Abstract Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. Congress:ASCO 2019, Search all connections
Abstract RNA-Seq analysis of glioma tumors to reveal targetable gene fusions. Congress:ASCO 2019, Search all connections
Abstract Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b. Congress:ASCO 2019, Search all connections
Abstract Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Congress:ASCO 2019, Search all connections
Abstract First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts). Congress:ASCO 2019, Search all connections
Abstract CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). Congress:ASCO 2019, Search all connections
Abstract IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas. Congress:ASCO 2019, Search all connections
Abstract Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Congress:ASCO 2019, Search all connections
Abstract Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression. Congress:ASCO 2019, Search all connections
Abstract Association between tumor biology and occult lymph node metastases before and after primary neoadjuvant therapy (NAT) for patients with early breast cancer. Congress:ASCO 2019, Search all connections
Abstract Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. Congress:ASCO 2019, Search all connections
Abstract A predictive model for survival in non-small cell lung cancer (NSCLC) based on electronic health record (EHR) and tumor sequencing data at the Department of Veterans Affairs (VA). Congress:ASCO 2019, Search all connections
Abstract A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. Congress:ASCO 2019, Search all connections
Abstract Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). Congress:ASCO 2019, Search all connections
Abstract Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. Congress:ASCO 2019, Search all connections
Abstract Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST. Congress:ASCO 2019, Search all connections
Abstract Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Congress:ASCO 2019, Search all connections
Abstract ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. Congress:ASCO 2019, Search all connections
Abstract Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Congress:ASCO 2019, Search all connections
Abstract Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). Congress:ASCO 2019, Search all connections
Abstract Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Congress:ASCO 2019, Search all connections
Abstract First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(Alliance A021202). Congress:ASCO 2019, Search all connections
Abstract Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. Congress:ASCO 2019, Search all connections
Abstract Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors. Congress:ASCO 2019, Search all connections
Abstract Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study. Congress:ASCO 2019, Search all connections
Abstract First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. Congress:ASCO 2019, Search all connections
Abstract Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. Congress:ASCO 2019, Search all connections
Abstract Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Congress:ASCO 2019, Search all connections
Abstract Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. Congress:ASCO 2019, Search all connections
Abstract Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. Congress:ASCO 2019, Search all connections
Abstract Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. Congress:ASCO 2020, Search all connections
Abstract Stress as a predictor of tumor growth and development of metastases. Congress:ASCO 2021, Search all connections
Abstract Overall survival (OS) and prognostic factors (PF) of patients (pts) with metastatic solid tumors admitted in intensive care unit (ICU). Congress:ASCO 2021, Search all connections
Abstract Differential risk factors between uterine sarcomas and malignant mixed Müllerian tumors. Congress:ASCO 2021, Search all connections
Abstract Trabectedin (T) in desmoplastic small round cell tumor (DSRCT): Report of its effect in 3 relapsed patients (pts) and the comparison of different regimens in a patient-derived xenograft (PDX) model. Congress:ASCO 2021, Search all connections
Abstract Desmoplastic small round cell tumor: A series of patients surgically treated at a single institution. Congress:ASCO 2021, Search all connections
Abstract Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors. Congress:ASCO 2021, Search all connections
Abstract A retrospective collection of diagnostic data from the desmoid tumor research foundation natural history study. Congress:ASCO 2021, Search all connections
Abstract Clinicopathological features and treatment of perivascular epithelioid cell tumor. Congress:ASCO 2021, Search all connections
Abstract Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors (GIST): A retrospective, multicenter, real-world study. Congress:ASCO 2021, Search all connections
Abstract Germline mutations in MSH2 and ATM gene in patients with GIST (Gastrointestinal stromal tumor) and second epitelial tumors. Congress:ASCO 2021, Search all connections
Abstract Changes of the redox-regulatory system in tumor and its surrounding tissues in patients with soft tissue sarcoma (STS) after neoadjuvant chemotherapy (NC). Congress:ASCO 2021, Search all connections
Abstract Various treatment options for the management of Campanacci III giant cell bone tumor. Congress:ASCO 2021, Search all connections
Abstract Role of biogenetic markers in differentiation and prognosis of giant cell tumor: A systemic review. Congress:ASCO 2021, Search all connections
Abstract Simultaneous stimulation of growth of malignant tumors with epithelioid and sarcomatous nature in experiment. Congress:ASCO 2021, Search all connections
Abstract Risk factors for 30-day readmissions in patients with tumor lysis syndrome and solid malignancies: Analysis from the National Readmission Database. Congress:ASCO 2021, Search all connections
Abstract Clinical behavior of advanced giant cell tumor: 15 years observation study in N.N. Blokhin National Medical Research Center of Oncology. Congress:ASCO 2021, Search all connections
Abstract Seminomatous and non-seminomatous mediastinal germ cell tumors (MGCT): A real-world analysis from two tertiary care centers in India. Congress:ASCO 2021, Search all connections